Daewoong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Daewoong Pharmaceutical has a total shareholder equity of ₩931.8B and total debt of ₩473.1B, which brings its debt-to-equity ratio to 50.8%. Its total assets and total liabilities are ₩1,808.5B and ₩876.7B respectively. Daewoong Pharmaceutical's EBIT is ₩126.3B making its interest coverage ratio 11. It has cash and short-term investments of ₩127.1B.
Key information
50.8%
Debt to equity ratio
₩473.13b
Debt
Interest coverage ratio | 11x |
Cash | ₩127.05b |
Equity | ₩931.79b |
Total liabilities | ₩876.69b |
Total assets | ₩1.81t |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A069620's short term assets (₩564.0B) do not cover its short term liabilities (₩689.3B).
Long Term Liabilities: A069620's short term assets (₩564.0B) exceed its long term liabilities (₩187.4B).
Debt to Equity History and Analysis
Debt Level: A069620's net debt to equity ratio (37.1%) is considered satisfactory.
Reducing Debt: A069620's debt to equity ratio has reduced from 63.4% to 50.8% over the past 5 years.
Debt Coverage: A069620's debt is well covered by operating cash flow (26.8%).
Interest Coverage: A069620's interest payments on its debt are well covered by EBIT (11x coverage).